Crossmark

Response to the letter to the Editor concerning manuscript entitled, “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide”

Crossref DOI link: https://doi.org/10.1007/s00520-020-05726-0

Published Online: 2020-09-03

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Affronti, Mary Lou https://orcid.org/0000-0003-4004-7834
Herndon, James E. II

Patel, Mallika P.
Funding

Funding for this research was provided by:

Original article funding: Merck provided aprepitant and funding for this Investigator-initiated study.
License Information

Text and Data Mining valid from 2020-09-03

Version of Record valid from 2020-09-03
More Information

Article History

Received: 17 August 2020

Accepted: 26 August 2020

First Online: 3 September 2020

Compliance with ethical standards

:

: Mary Lou Affronti has been supported by Eisai and Merck for investigator-initiated clinical trials and served as an antiemetic expert advisory board member with Eisai for NEPA (2013–2014) and for Merck on an Advisory Expert Input forum (2017). All other authors declare no conflict of interest at this time.

Document is current

Any future updates will be listed below